Switch View
© PR Newswire
30.10.2025
ISIN: US70387R4039
PAVmed, Inc.
PAVM
LISTED
NASDAQ
PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025
News Preview
Conference Call and Webcast at 8:30 AM Eastern Time
NEW YORK, Oct. 30, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digit...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
ISIN: US58155Q1031
McKesson Corp
MCK
LISTED
NYSE
McKesson Corporation Declares Quarterly Dividend
News Preview
The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 82 cents per share of common stock. The dividend will be payable on January 2, 2026 to shareholders of record on December 1, 2025.
About McKesson Corporation
McKesson Corporation is a diversified healthcare services leader dedicated to advancing...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
ISIN: US02043Q1076
Alnylam Pharmaceuticals Inc
ALNY
LISTED
NASDAQ
Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2025 and reviewed recent business highlights.
“Alnylam’s impressive third quarter financial results underscore our ability to consistently deliver innovative medicines to...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
30.10.2025
ISIN: US53566P1093
Lineage Cell Therapeutics Inc.
LCTX
LISTED
TLV
Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced that it will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025, following the close of the U.S. fi...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
30.10.2025
ISIN: US89680M1018
TriSalus Life Sciences, Inc.
TLSI
LISTED
NASDAQ
TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call
News Preview
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a conference call and webcast on Thursday November 13, 2025 at 4:30 PM eastern time to discuss...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte to Present at Upcoming Investor Conferences
News Preview
Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November:
Guggenheim Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 10:00 am (EST)
Jefferies Global Healthcare Conference (London) on Tuesday, November 18, 2025 at 11:00 am (GMT)
The presentations w...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
ISIN: US51654W1018
Lantern Pharma Inc.
LTRN
LISTED
NASDAQ
Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN)— Lantern today announced it will present two commercially deployed AI research platforms at the inaugural AI for Biology and Medicine (AI4BM) symposium at the University of North Texas. The symposium, hosted by Dr. Serdar Bozdag and the newly established Center for Computational Life Sciences, brings together lea...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2025
ISIN: US6700021040
Novavax Inc
NVAX
LISTED
NASDAQ
Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025
News Preview
GAITHERSBURG, Md., Oct. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its third quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, November 6, 2025. Details of the event and replay are as follows:...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
ISIN: US64131A1051
Neuronetics Inc
STIM
LISTED
NASDAQ
Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence
News Preview
New collaboration provides services to streamline patient support, reduce administrative burden, and expand access to advanced TMS treatment across Elite DNA Clinics New collaboration provides services to streamline patient support, reduce administrative burden, and expand access to advanced TMS treatment across Elite DNA Clinics...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
ISIN: US5288723027
Lexicon Pharmaceuticals Inc
LXRX
LISTED
NASDAQ
Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
News Preview
THE WOODLANDS, Texas, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its third quarter 2025 financial results on Thursday, November 6, 2025, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss th...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
Baxter Reports Third-Quarter 2025 Results
News Preview
Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2025.
“I joined Baxter because it’s a global healthcare leader – an iconic brand with an essential portfolio that touches more than 350 million patients every year,” said Andrew Hider, president and CEO. “In my first weeks, I’ve seen fi...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2025
ISIN: US59267L1070
Metsera, Inc.
MTSR
LISTED
NASDAQ
Metsera Receives Unsolicited Proposal from Novo Nordisk
News Preview
Metsera Declares Novo Nordisk Proposal "Superior"
Novo Nordisk Proposal Values Metsera at up to $77.75 per Share, a Total of Approximately $9 Billion
Pursuant to Pfizer Merger Agreement, Metsera and Pfizer May...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
30.10.2025
ISIN: US75901B1070
Regenxbio Inc
RGNX
LISTED
NASDAQ
REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program
News Preview
Patients treated with RGX-202 demonstrate consistent, robust microdystrophin expression and functional improvement compared to natural history in Phase I/II portion of AFFINITY DUCHENNE® trial supporting potential approval via the accelerated approval pathway...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
ISIN: US42238H1086
HeartBeam, Inc.
BEAT
LISTED
NASDAQ
HeartBeam to Host Third Quarter 2025 Results Conference Call on Thursday, November 13, 2025 at 4:30 p.m. Eastern Time
News Preview
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Thursday, November 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2025, and will be providing updates on regulatory initia...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
ISIN: US6323071042
Natera Inc
NTRA
LISTED
NASDAQ
Natera to Report its Third Quarter Results on November 6, 2025
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its third quarter ended September 30, 2025, after the market closes on November 6, 2025. Natera will host a conference call and webcast shortly thereafter at 4:30 p.m. ET.
Earnings Conference Call Information...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure Reports Third Quarter 2025 Financial Results
News Preview
Novocure (NASDAQ: NVCR) today reported financial results for the third quarter that ended September 30, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).
“Q3 was a solid quarter with stea...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
ISIN: US4834971032
Kalvista Pharmaceuticals Inc
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of one abstract for late-breaking oral presentation and three for poster presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting taking place in Orlando, Florida from November 6–10, 2025.
The lake-breaking oral pre...
Themefolio
Profiler
Peergroup
© Newsfile
30.10.2025
ISIN: CA74141E1043
PreveCeutical Medical Inc.
PREV
LISTED
CSE
PreveCeutical Closes Second Tranche of Non-Brokered Private Placement
News Preview
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - October 30, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases of August 5, 2025, Sep...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
ISIN: US23284F1057
CytomX Therapeutics Inc
CTMX
LISTED
NASDAQ
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
News Preview
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 6, 2025, after the close of U.S. markets. Following the announcement, the Company wil...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
ISIN: US09077A1060
Biomea Fusion Inc
BMEA
LISTED
NASDAQ
Biomea Fusion to Present Poster Presentations at ObesityWeek®2025
News Preview
SAN CARLOS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that it will present poster presentations at ObesityWeek® 2025, taking place November 4-7, 2025 in Atlanta, Georgia....
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
ISIN: ES0167733015
Oryzon Genomics SA
ORY
LISTED
BME
ORYZON to Participate in Upcoming Events in November
News Preview
MADRID, Spain and CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events:...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
ISIN: US6951271005
Pacira Biosciences Inc
PCRX
LISTED
NASDAQ
Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025
News Preview
BRISBANE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its third quarter financial results after the close of the U.S. markets on Thursday November 6,...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
ISIN: US87427V1035
Talkspace Inc
TALK
LISTED
NASDAQ
Talkspace Announces Third Quarter 2025 Results
News Preview
3Q 2025 Total revenue grew 25% year-over-year to $59.4 million driven by 42% year-over-year growth in Payor revenue...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2025
ISIN: US23283X2062
Cytosorbents Corp
CTSO
LISTED
NASDAQ
CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights
News Preview
PRINCETON, N.J., Oct. 30, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2025 financial results and recent business highlights after the market...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
ISIN: US1101221083
Bristol-Myers Squibb Co
BMY
LISTED
NYSE
Bristol Myers Squibb Reports Third Quarter Financial Results for 2025
News Preview
Bristol Myers Squibb (NYSE: BMY) today reported third quarter 2025 financial results.
Visit the company’s Investor Relations website at http://investor.bms.com to view the detailed third quarter 2025 earnings press release and investor presentation.
The company will host a conference call and live audio webcast for analysts and investors at 8:...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
ISIN: US7170811035
Pfizer Inc
PFE
LISTED
NYSE
Pfizer Addresses Proposal for Metsera
News Preview
Pfizer Inc. (NYSE: PFE) is aware of the reckless and unprecedented proposal by Novo Nordisk A/S (NYSE: NVO) to acquire Metsera, Inc. (NASDAQ: MTSR). It is an attempt by a company with a dominant market position to suppress competition in violation of law by taking over an emerging American challenger. It is also structured in a way to circumvent a...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2025
ISIN: US14149Y1082
Cardinal Health Inc
CAH
LISTED
NYSE
Cardinal Health Reports First Quarter Fiscal Year 2026 Results and Raises Outlook
News Preview
Revenue increased 22% to $64 billion
GAAP
1
operating earnings increased 18% to $668 million; GAAP diluted EPS increased 11% to $1.88...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
ISIN: KYG211081248
China Medical System Holdings Ltd
867
LISTED
HKSE
CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Rα Humanized Monoclonal Antibody Injection MG-K10 Accepted in China
News Preview
SHENZHEN, CHINA, Oct. 30, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, p...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
ISIN: US68213N1090
Omnicell Inc
OMCL
LISTED
NASDAQ
Omnicell Announces Third Quarter 2025 Financial Results
News Preview
Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its third quarter ended September 30, 2025.
“We are pleased with the strong financial performance delivered in the third quarter, with total revenues, non...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results
News Preview
Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2025.
“In the third quarter, we continued to execute on our strategy with important pipeline advancements, significant approvals and successful new product launches,” said Robert M. D...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
ISIN: CA4990531069
Knight Therapeutics Inc
GUD
LISTED
TSX
Notice of Knight Therapeutics' Third Quarter 2025 Results Conference Call
News Preview
MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2025 financial results on Thursday, November 6, 2025 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordi...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
ISIN: CA4990531069
Knight Therapeutics Inc
GUD
LISTED
TSX
Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina
News Preview
MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A. has obtained the regulatory approval and has launched MINJUVI® in Argentina. Knight obtained approval from the Argentinian health r...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
ISIN: US02155H1014
Altimmune, Inc.
ALT
LISTED
NASDAQ
Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
News Preview
GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it will report its third quarter 2025 financial results on Thursday, November 6, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
ISIN: US3441741077
Foghorn Therapeutics Inc
FHTX
LISTED
NASDAQ
Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
News Preview
- Data presented at the TPD and Induced Proximity Summit demonstrate that novel Selective ARID1B degrader selectively binds and degrades ARID1B; potentially relevant in up to 5% of all solid tumors ...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
ISIN: US8269171067
SIGA Technologies Inc
SIGA
LISTED
NASDAQ
SIGA to Host Business Update Call on November 6, 2025 Following Release of Third-Quarter 2025 Results
News Preview
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 6, 2025. Participating in the call will be Diem Nguyen, Chief Executive Off...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2025
ISIN: SE0010323311
BioArctic AB
BIOA B
LISTED
STO
Sales of Leqembi® totaled 18 billion yen in the third quarter 2025
News Preview
STOCKHOLM, Oct. 30, 2025 /PRNewswire/ -- BioArctic AB's (publ) (STO: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the third quarter 2025, in conjunction with their partner Biogen's third quarter report. In total, sales of JPY 18 billion were recorded in the period. This...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
ISIN: US03753U1060
Apellis Pharmaceuticals Inc
APLS
LISTED
NASDAQ
Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results
News Preview
WALTHAM, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its third quarter 2025 financial results and business highlights....
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
ISIN: US88688T1007
Tilray Brands Inc
TLRY
LISTED
TSX
Tilray Brands Sets Sights on Asia: Bringing Award-Winning Craft Beers to Japan’s Premier American Craft Beer Experience Festival
News Preview
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, is bringing its celebrated craft beer brands to the heart of Asia. Tilray will debut select craft brands at the highly anticipated...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
ISIN: US71722W1071
Phathom Pharmaceuticals Inc
PHAT
LISTED
NASDAQ
Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
FLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the third quarter ended September 30, 2025, and provided a business update....
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
ISIN: US68404L2016
Option Care Health Inc
OPCH
LISTED
NASDAQ
Option Care Health Announces Financial Results For the Third Quarter Ended September 30, 2025
News Preview
BANNOCKBURN, Ill., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the third quarter ended September 30, 2025....
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2025
ISIN: US1255091092
Cigna Group (The)
CI
LISTED
NYSE
The Cigna Group Reports Strong Third Quarter 2025 Results, Reaffirms 2025 Adjusted EPS Outlook
News Preview
Total revenues for the third quarter 2025 increased 10% to $69.7 billion
Shareholders' net income for the third quarter 2025 was $1.9 billion, or $6.98 per share
Adjusted income...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
ISIN: US00847X1046
Agios Pharmaceuticals Inc
AGIO
LISTED
NASDAQ
Agios Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
Agios today announced financial results and updates for the third quarter ended September 30, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
ISIN: US09075X1081
Biodesix Inc
BDSX
LISTED
NASDAQ
Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting
News Preview
Speaker panel will include collaborative case study presentations from strategic partners: Memorial Sloan Kettering Cancer Center, Bio-Rad Laboratories, and Thermo Fisher Scientific Speaker panel will include collaborative case study presentations from strategic partners: Memorial Sloan Kettering Cancer Center, Bio-Rad Laboratories, and Thermo Fish...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
ISIN: US4579852082
Integra Lifesciences Holdings Corp
IART
LISTED
NASDAQ
Integra LifeSciences Reports Third Quarter 2025 Financial Results
News Preview
PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
ISIN: US03168L1052
Amneal Pharmaceuticals Inc
AMRX
LISTED
NASDAQ
Amneal Reports Third Quarter 2025 Financial Results
News Preview
‒ Q3 2025 Net Revenue of $785 million; GAAP Net Income of $2 million; Diluted Income per Share of $0.01 ‒‒ Adjusted EBITDA of $160 million; Adjusted Diluted EPS of $0.17 ‒‒ Updated 2025 Full Year Guidance ‒...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
ISIN: DK0062498333
Novo Nordisk A/S
NOVO B
LISTED
CPH
Novo Nordisk submits proposal to acquire Metsera, Inc.
News Preview
Bagsværd, Denmark, 30 October 2025 – Novo Nordisk confirms that it submitted an unsolicited proposal to acquire Metsera, Inc. (Metsera)....
Themefolio
Profiler
Peergroup
© ACCESSWIRE
30.10.2025
ISIN: US29350E1047
Enochian Biosciences, Inc
ENOB
LISTED
NASDAQ
Lunai Bioworks Harnesses AI and Zebrafish Data to Advance Early Detection of Neurotoxic Compounds
News Preview
NEW YORK, NY / ACCESS Newswire / October 30, 2025 / In the face of growing global concern over the potential use of chemical weapons such as the nerve agent Sarin, Lunai Bioworks Inc. (NASDAQ:LNAI) today announced promising early results from its AI-based platform designed to identify compounds that interact with acetylcholinesterase (AChE), the sa...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
ISIN: US45784P1012
Insulet Corp
PODD
LISTED
NASDAQ
Insulet Champions Workplace Inclusion for People with Diabetes with New Data and Tools Released for Diabetes Awareness Month
News Preview
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its new campaign, “The Day Diabetes Showed Up to Work,” in honor of Diabetes Awareness Month, which starts November 1.
“Nearly 590 million people worldwide live with diabetes1, an...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2025
ISIN: KR7068270008
Celltrion Inc
68270
LISTED
KSC
U.S. FDA grants interchangeability designation to Celltrion's denosumab biosimilars, STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo)
News Preview
The U.S. FDA approved STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) as interchangeable with the reference products PROLIA® (denosumab) and XGEVA® (denosumab), respectively, for all approved indications, effective as of October 29, 2025
The interchangeability (IC) designations of STOB...
Themefolio
Profiler
Peergroup
© EQS Newswire
30.10.2025
ISIN: JP3463000004
Takeda Pharmaceutical Co Ltd
45020
LISTED
XJPX
Notice of the Revised Forecast of Consolidated Financials for FY2025 (IFRS)
News Preview
News Release
Notice of the Revised Forecast of Consolidated Financials for FY2025 (IFRS)
OSAKA, Japan, October 30, 2025 – Takeda (TSE:4502/NYSE:TAK) today announced the revised forecast of the full year consolidated financials for the fiscal year ending March 31, 2026 (FY2025), as below.
Takeda’s fiscal year 2025 first half results a......
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2025
ISIN: SE0002148817
Hansa Biopharma AB
HNSA
LISTED
STO
Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results
News Preview
Imlifidase successfully met primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation.
First clinical data supports imlifidase ability to substantially reduce anti-AAV antibodies to allow administration of gene t...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2025
ISIN: SE0002148817
Hansa Biopharma AB
HNSA
LISTED
STO
Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results
News Preview
Imlifidase successfully met primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation.
First clinical data supports imlifidase ability to substantially reduce anti-AAV antibodies to allow administration of gene t...
Themefolio
Profiler
Peergroup
© EQS Newswire
30.10.2025
ISIN: CH1243598427
Sandoz Group AG
SDZ
LISTED
XWSX
Sandoz delivers a further acceleration in sales growth; full-year margin guidance upgraded
News Preview
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
Basel, October 30, 2025 - Sandoz (SIX: SDZ / OTCQX: SDZNY), the global leader in affordable medicines, today presents its net-sales performance for the nine months and third quarter ended September 30, 2025.
9M net sales of USD 8,057 million
up by 5% at constant currencies (C......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.10.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon lädt zur Telefonkonferenz zum Neunmonatsergebnis 2025 ein und gibt Teilnahme an Investorenkonferenzen im 4. Quartal 2025 bekannt
News Preview
Pressemitteilung // 30. Oktober 2025
Formycon lädt zur Telefonkonferenz zum Neunmonatsergebnis 2025 ein und gibt Teilnahme an Investorenkonferenzen im 4. Quartal 2025 bekannt
Planegg-Martinsried – Die Formycon AG (FWB: FYB, Prime Standard, „Formycon“) plant die Neunmonatszahlen 2025 am 13. November 2025 zu veröffentlichen. Der Vorstand wird di......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.10.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon invites to Conference Call on 2025 Nine-Month Results and announces Participation in Investor Conferences in the 4th Quarter of 2025
News Preview
Press Release // October 30, 2025
Formycon invites to Conference Call on 2025 Nine-Month Results and announces Participation in Investor Conferences in the 4th Quarter of 2025
Planegg-Martinsried, Germany – Formycon AG (FSB: FYB, Prime Standard, „Formycon“) plans to publish its Nine-Month Results 2025 on November 13, 2025. The Management Boar......
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
ISIN: CH0012032048
Roche Holding AG
ROG
LISTED
SIX
Roche purchases shares in tender offer for 89bio, Inc
News Preview
Basel, 30 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche’s wholly owned subsidiary Bluefin Merger Subsidiary, Inc., has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of 89bio, Inc. (“89bio”, NASDAQ: ETNB) at a price of...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
ISIN: CH0363463438
Idorsia Ltd
IDIA
LISTED
SIX
QUVIVIQ sales up >130% driving Idorsia toward profitability – 9M 2025 results
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
ISIN: US2521311074
Dexcom Inc
DXCM
LISTED
NASDAQ
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. (“DexCom” or “the Company”) (NASDAQ: DXCM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2025
ISIN: KYG3224E1061
Everest Medicines Limited
1952
LISTED
HKSE
Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders
News Preview
Everest Medicines acquired an exclusive license to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and certain Southeast Asian countries.
Under the assigned exclusive license, Everest Medicines will make an upfront payment of US$7 million (equivalent to...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
ISIN: KYG4783B1032
Innocare Pharma Limited
9969
LISTED
HKSE
Latest Data of InnoCare's Zurletrectinib Orally Presented at SIOP 2025
News Preview
Zurletrectinib demonstrated well-tolerated safety and promising antitumor activity in pediatric/adolescent patients with NTRK/ROS1-altered solid tumors....
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
